Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jun 19

PMID 38892731

Authors

Jodie L M Tham

Sweet Ping Ng

Richard Khor

Morikatsu Wada

Hui Gan

Alesha A Thai

June Corry

Houda Bahig

Antti A Makitie

Sandra Nuyts

Remco de Bree

Primoz Strojan

Wai Tong Ng

Avraham Eisbruch

James C H Chow

Alfio Ferlito

Affiliations

Soon will be listed here.

Abstract

The treatment of head and neck cancers (HNCs) encompasses a complex paradigm involving a combination of surgery, radiotherapy, and systemic treatment. Locoregional recurrence is a common cause of treatment failure, and few patients are suitable for salvage surgery. Reirradiation with conventional radiation techniques is challenging due to normal tissue tolerance limits and the risk of significant toxicities. Stereotactic body radiotherapy (SBRT) has emerged as a highly conformal modality that offers the potential for cure while limiting the dose to surrounding tissue. There is also growing research that shows that those with oligometastatic disease can benefit from curative intent local ablative therapies such as SBRT. This review will look at published evidence regarding the use of SBRT in locoregional recurrent and oligometastatic HNCs.

References

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Bonomo P, Greto D, Desideri I, Loi M, Di Cataldo V, Orlandi E . Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. Oral Oncol. 2019; 93:1-7. DOI: 10.1016/j.oraloncology.2019.04.006. View

Heron D, Ferris R, Karamouzis M, Andrade R, Deeb E, Burton S . Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009; 75(5):1493-500. DOI: 10.1016/j.ijrobp.2008.12.075. View

Gogineni E, Zhang I, Rana Z, Marrero M, Gill G, Sharma A . Quality of Life Outcomes Following Organ-Sparing SBRT in Previously Irradiated Recurrent Head and Neck Cancer. Front Oncol. 2019; 9:836. PMC: 6746961. DOI: 10.3389/fonc.2019.00836. View

Mancosu P, Lambri N, Castiglioni I, Dei D, Iori M, Loiacono D . Applications of artificial intelligence in stereotactic body radiation therapy. Phys Med Biol. 2022; 67(16). DOI: 10.1088/1361-6560/ac7e18. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Cengiz M, Ozyigit G, Yazici G, Dogan A, Yildiz F, Zorlu F . Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2010; 81(1):104-9. DOI: 10.1016/j.ijrobp.2010.04.027. View

Curtis K, Ross H, Garrett A, Jizba T, Patel A, Patel S . Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic. Radiat Oncol. 2016; 11:55. PMC: 4826496. DOI: 10.1186/s13014-016-0630-x. View

Singh R, Jenkins J, Davis J, Song S, Sharma S, Austin Vargo J . A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck. J Radiosurg SBRT. 2022; 8(1):11-19. PMC: 8930056. View

10.

Khan L, Tjong M, Raziee H, Lee J, Erler D, Chin L . Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients. Support Care Cancer. 2014; 23(4):1099-103. DOI: 10.1007/s00520-014-2421-y. View

11.

Mahmood U, Bang A, Chen Y, Mak R, Lorch J, Hanna G . A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2020; 109(1):134-144. PMC: 9361179. DOI: 10.1016/j.ijrobp.2020.08.018. View

12.

Quan K, Xu K, Zhang Y, Clump D, Flickinger J, Lalonde R . Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma. Semin Radiat Oncol. 2016; 26(2):112-9. DOI: 10.1016/j.semradonc.2015.11.007. View

13.

Rwigema J, Heron D, Ferris R, Andrade R, Gibson M, Yang Y . The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2010; 34(4):372-9. PMC: 3177149. DOI: 10.1097/COC.0b013e3181e84dc0. View

14.

Vengaloor Thomas T, Packianathan S, Bhanat E, Albert A, Abraham A, Gordy X . Oligometastatic head and neck cancer: Comprehensive review. Head Neck. 2020; 42(8):2194-2201. DOI: 10.1002/hed.26144. View

15.

Iwata H, Tatewaki K, Inoue M, Yokota N, Sato K, Shibamoto Y . Salvage stereotactic reirradiation using the CyberKnife for the local recurrence of nasal or paranasal carcinoma. Radiother Oncol. 2012; 104(3):355-60. DOI: 10.1016/j.radonc.2012.01.017. View

16.

Kress M, Sen N, Unger K, Lominska C, Deeken J, Davidson B . Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. Head Neck. 2014; 37(10):1403-9. DOI: 10.1002/hed.23763. View

17.

Bates J, De Leo A, Morris C, Amdur R, Dagan R . Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single-institution outcomes. Head Neck. 2019; 41(7):2309-2314. DOI: 10.1002/hed.25695. View

18.

Yazici G, Sanli T, Cengiz M, Yuce D, Gultekin M, Hurmuz P . A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat Oncol. 2013; 8:242. PMC: 4016484. DOI: 10.1186/1748-717X-8-242. View

19.

Lop J, Venegas M, Pujol A, Sauter B, Vasquez R, Casasayas M . Causes of long-term mortality in patients with head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2021; 279(7):3657-3664. PMC: 9130168. DOI: 10.1007/s00405-021-07211-8. View

20.

Langer C, Harris J, Horwitz E, Nicolaou N, Kies M, Curran W . Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25(30):4800-5. DOI: 10.1200/JCO.2006.07.9194. View